ZAK) after correction for multiple comparisons by a false discovery rate (FDR) <0.20.
After removal of three CSNK2B SNPs that are located in the same locus previously reported by GWAS, we performed the LD analysis and found that rs3769201 and rs7604288 were in high LD. We then chose two independent representative SNPs of rs3769201 and rs722864 in ZAK for further analysis. We also expanded the analysis by including these two SNPs from additional GWAS datasets of Harvard University (984 cases and 970 controls) and deCODE (1319 cases and 26 380 controls). The overall effects of these two SNPs were assessed using all eight GWAS datasets (OR = 0.92, 95%CI = 0.89-0.95, and P = 1.03 × 10 −5 for rs3769201; OR = 0.91, 95% CI = 0.88-0.95, and P = 2.03 × 10 −6 for rs722864). Finally, we performed an expression quantitative trait loci (eQTL) analysis and found that these two SNPs were significantly associated with ZAK mRNA expression levels in lymphoblastoid cell lines. In conclusion, the ZAK rs3769201 and rs722864 may be functional susceptibility loci for lung cancer risk.
Several studies have shown that TP53 24, 25 and ATM 26 in the P38MAPK signaling pathway are associated with lung cancer risk, but these studies did not include many other candidate genes and SNPs of this pathway. In the present study, we were further motivated to comprehensively investigate this pathway, because associations between genetic variants in the P38MAPK pathway genes and lung cancer risk are collectively more significant than what would be expected by chance (see section 2).
2 | METHODS
| Study populations
We used the summary data from the Transdisciplinary Research Overall, 108 genes located on autosomal chromosomes were selected (details presented in Supplementary Table S1 ). There were 14 904 SNPs within these selected genes with 2 kb upstream and 2 kb downstream with the following selection criteria: (1) minor allele frequency (MAF) ≥5%; (2) genotyping rate ≥95%; and (3) Hardy-Weinberg Equilibrium (HWE) exact P-value ≥ 10 −5 . The detailed workflow is shown in Figure 1 . P values from lung cancer GWAS meta-analysis of these SNPs significantly deviated from the null distribution, with Kolmogorov-Smirnov test P = 4.67 × 10 −6 .
| In silico functional prediction and validation
SNPinfo, 32 RegulomeDB, 33 and HaploReg 34 were used to predict SNPassociated potential functions. The expression quantitative trait loci (eQTL) analysis was performed by using the genotyping and expression data available from the lymphoblastoid cell data of 373 European individuals from Genetic European Variation in Health and Disease Consortium (GEUVADIS) and the 1000 Genomes Project (phase I integrated release 3, March 2012). 35 We also performed eQTL and differential expression analyses by using expression data of both tumor and adjacent normal tissues from the Cancer Genome Atlas (TCGA) 38 was employed to generate the regional association plots. 38 The Manhattan plot and linkage disequilibrium (LD) plots were generated by Haploview v4.2.
We used the LD analysis in choosing representative SNPs of the 3 | RESULTS
| Analysis of the six GWAS datasets
In total, 14 904 SNPs from 108 genes were available from the six Table 1 . We excluded three SNPs in CSNK2B, because they are located on the same locus (6p21.33) previously reported by a GWAS. 39 Based on LD analysis 
| Functional validation by the eQTL analysis
We performed the eQTL analysis to assess the associations between SNPs and their gene mRNA expression levels in the lymphoblastoid cell lines from 373 subjects of European ancestry in the 1000 Genomes project, and we found that ZAK rs3769201 and rs722864 were associated with ZAK mRNA expression levels in an additive model | 219 marginally significantly correlation with ZAK mRNA expression levels in the primary tumor tissues of patients with lung squamous cell carcinoma (P = 0.067 and 0.069 for rs3769201 and rs722864, respectively. Supplementary Figures S2C and S2D ). In addition, we compared mRNA expression levels of ZAK in 109 paired target tissue samples with normal adjacent tissue samples from the TCGA database and found that ZAK mRNA expression levels were also significantly decreased in the tumor tissues compared to the normal tissues (P = 6.29E-08), as well as stratified by adenocarcinoma (AD) and squamous cell lung carcinoma (SC) (Figure 3) . Therefore, rs3769201 and rs722864 were chosen as the representative SNPs for further analyses because they were significantly associated with lung cancer risk as assessed in the overall association analysis and had potential functions according to the eQTL analysis.
| Expanded analysis by additional two GWASs
We sought to expand our analysis by two additional independent lung cancer GWASs, Harvard Lung Cancer Study (Harvard) and Icelandic Lung Cancer Study (deCODE). We subsequently performed an overall meta-analysis to evaluate associations between the two ZAK SNPs and lung cancer risk in all eight GWASs. We found the overall effect of these two SNPs from among all eight GWASs remained significant (OR = 0.92, 95%CI = 0.89-0.95, P-value of heterogeneity test
[Phet] = 0.471, and P = 1.03E-05 for rs3769201 and OR = 0.91, 95% CI = 0.88-0.95, Phet = 0.504, and P = 2.03E-06 for rs722864) ( Table 2 and Supplementary Figures S3A and S3B ).
In subgroup analysis by histology ( Table 2 Figure S3A ). We also found that the rs722864A allele was associated with lung cancer risk among ever smokers (OR = 0.89, 95%CI = 0.85-0.94, P = 5.58E-05), but not among never smokers (OR = 0.95, 95%CI = 0.80-1.12, P = 0.520) ( Figure S3B) . However, heterogeneity test showed that the effect difference between ever smokers and never smokers was statistically non-significant for both SNPs (Phet = 0.349 for rs3769201 and Phet = 0.467 for rs722864). There is also no significant difference between AD and SC by heterogeneity test (Phet = 0.223 for rs3769201 and Phet = 0.524 for rs722864).
| DISCUSSION
In the present study, we used eight published GWASs from the TRICL-ILCCO consortium to investigate the associations between genetic variants in P38MAPK pathway genes and lung cancer risk. We found that two novel, potentially functional SNPs, that is, rs3769201T and rs722864A alleles of ZAK, were associated with both a decreased lung cancer risk and a decreased mRNA expression level of ZAK. We also demonstrated that the rs3769201T and rs722864A alleles were significantly associated with risk of both lung AD and SC among ever smokers.
The P38 signaling cascade activation is triggered by several by inhibiting lung cancer growth. 42 However, more evidence supports that ZAK may have a pro-oncogenic function. For example, the TCGA data showed significantly higher ZAK mRNA expression levels in lung cancer tissues than adjacent normal tissues in cancers of the bladder, breasts, and stomach. Others showed that the overexpression of ZAK-α activated several cancer-related signaling genes, such as AP1 and NF-kB 43 and that ZAK also participate in cell proliferation in gastric cell lines 44 as well as enhanced human colon cancer HCT116 cell EGF-dependent motility and migration. 45 These studies were
The mRNA expression levels of ZAK in the 109 paired lung cancer and normal adjacent tissue samples from the TCGA database (A, over all, P = 6.29 × 10 −8 ; B, squamous cell carcinoma, P = 0.069; C, adenocarcinoma, P = 1.55 × 10 −9 ). The deCORE data was allowed to be used for calculation in the meta-analysis but cannot be shown according to the deCODE's requirement. We also performed subgroup analysis by histology and smoking status, and we demonstrated that both rs3769201T and rs722864A alleles were associated with risk of SC and ever smokers, but not with AD and never smokers. Cigarette smoke is the major risk factor for lung cancer, especially for SC. It has been reported that the transcription factor (TF) STAT can be activated after tobacco smoke exposure. 46 Functional prediction analysis from HaploReg showed that rs3769201 had a STAT binding site motif, and the results of eQTL in the present study also demonstrated that the SNP may alter the mRNA expression of ZAK. However, there is no significant difference between ever smokers and never smokers as tested by the heterogeneity test.
The present study has some limitations. First of all, although we found five relevant pathways from the Molecular Signatures Database, perhaps some newly discovered genes may not have been included yet. Second, some published studies support that ZAK is an oncogene, 44 but others have shown that ZAK may have the function of suppressing cancer growth. 42 More biological and molecular experiments should be performed to reveal the mechanisms underlying the observed associations. Finally, the analyses have not been adjusted for potentially important baseline risk covariates including family history.
In conclusion, the present study of eight published GWASs revealed two novel, potentially functional susceptibility loci in ZAK associated with lung cancer risk in European populations. Further functional evaluations of these genetic variants are warranted to verify our findings. GWAS, genome-wide association study; OR, odds ratio; CI, confidence interval. NCI GWAS includes four sub-studies: the alpha-tocopherol, beta-carotene cancer prevention study (ATBC), the cancer prevention study II nutrition cohort (CPS-II), the environment and genetics in lung cancer etiology (EAGLE), and the prostate, lung, colon, ovary screening trial (PLCO). 
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